journal article·2024-11-06Open access

Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody

Sara Insausti, Ander Ramos-Caballero, Brian Wiley, Saul González-Resines, Johana Torralba, Anne Elizaga-Lara, Christine Shamblin, Akio Ojida, Jose M. M. Caaveiro, Michael B. Zwick, Edurne Rujas, Carmen Domene, José L. Nieva

ACS Applied Materials & Interfaces· Volume 16· Issue 44

Abstract

Establishment of interactions with the envelope lipids is a cardinal feature of broadly neutralizing antibodies (bnAbs) that recognize the Env membrane-proximal external region (MPER) of HIV. The lipid envelope constitutes a relevant component of the full "quinary" MPER epitope, and thus antibodies may be optimized through engineering their capacity to interact with lipids. However, the role of the chemically complex lipid nanoenvironment in the mechanism of MPER molecular recognition and viral neutralization remains poorly understood. To approach this issue, we computationally and experimentally investigated lipid interactions of broadly neutralizing antibody 10E8 and optimized versions engineered to enhance their epitope and membrane affinity by grafting bulky aromatic compounds. Our data revealed a correlation between neutralization potency and the establishment of favorable interactions with small headgroup lipids cholesterol and phosphatidylethanolamine, evolving after specific engagement with MPER. Molecular dynamics simulations of chemically modified Fabs in complex with an MPER-Transmembrane Domain helix supported the generation of a nanoenvironment causing localized deformation of the thick, rigid viral membrane and identified sphingomyelin preferentially occupying a phospholipid-binding site of 10E8. Together, these interactions appear to facilitate insertion of the Fabs through their engagement with the MPER epitope. These findings implicate individual lipid molecules in the neutralization function of MPER bnAbs, validate targeted chemical modification as a method to optimize MPER antibodies, and suggest pathways for MPER peptide-liposome vaccine development.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: HIV Research and Treatment · Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Instituto Biofisika (CSIC, UPV/EHU)

University of the Basque Country (UPV/EHU)

Department of Biochemistry and Molecular Biology

Department of Chemistry, University of Bath, Claverton Down, Bath BA2 7AX, United Kingdom

Department of Immunology and Microbiology

The Scripps Research Institute

Department of Chemical Biology, School of Pharmaceutical Sciences

Kyushu University

Laboratory of Protein Drug Discovery, School of Pharmaceutical Sciences

Department of Pharmacy and Food Sciences, Faculty of Pharmacy

Basque Foundation for Science

Ikerbasque

Funding

Engineering and Physical Sciences Research Council · UK Research and Innovation · Japan Agency for Medical Research and Development · Eusko Jaurlaritza · Euskal Herriko Unibertsitatea · National Institutes of Health · H2020 European Research Council · Spanish MCIN/AEI

References (70)

Show source-provided references
1. 10.1097/COH.000000000000055010.1097/COH.0000000000000550 ↗
2. 10.1038/s41577-022-00753-w10.1038/s41577-022-00753-w ↗
3. 10.1146/annurev-immunol-041015-05551510.1146/annurev-immunol-041015-055515 ↗
4. 10.1038/nature1154410.1038/nature11544 ↗
5. 10.1128/JVI.02097-1510.1128/JVI.02097-15 ↗
6. 10.1128/JVI.03246-1510.1128/JVI.03246-15 ↗
7. Rujas E. · J. Virol · 2018 · 92 · e0224910.1128/JVI.02249-17 ↗
8. 10.1016/j.celrep.2018.01.02310.1016/j.celrep.2018.01.023 ↗
9. Pegu A. · Sci. Transl Med. · 2014 · 6 · 243ra28810.1126/scitranslmed.3008992 ↗
10. 10.1371/journal.ppat.100427110.1371/journal.ppat.1004271 ↗
11. 10.1016/j.tim.2014.08.00610.1016/j.tim.2014.08.006 ↗
12. Spencer D. A. · Nat. Commun. · 2022 · 13 · 66210.1038/s41467-022-28250-7 ↗
13. 10.1016/j.cell.2016.05.02410.1016/j.cell.2016.05.024 ↗
14. Rujas E. · Proc. Natl. Acad. Sci. U. S. A. · 2022 · 119 · e211288711910.1073/pnas.2112887119 ↗
15. 10.1371/journal.ppat.101146910.1371/journal.ppat.1011469 ↗
16. 10.1016/j.celrep.2020.10758310.1016/j.celrep.2020.107583 ↗
17. 10.1016/j.sbi.2024.10289710.1016/j.sbi.2024.102897 ↗
18. Rujas E. · Sci. Rep · 2016 · 6 · 3817710.1038/srep38177 ↗
19. 10.1371/journal.ppat.100621210.1371/journal.ppat.1006212 ↗
20. 10.4049/jimmunol.178.7.442410.4049/jimmunol.178.7.4424 ↗
21. 10.1073/pnas.090968010710.1073/pnas.0909680107 ↗
22. 10.3390/ijms23181076710.3390/ijms231810767 ↗
23. 10.1016/bs.apcsb.2015.03.00210.1016/bs.apcsb.2015.03.002 ↗
24. Williams W. B. · Cell · 2024 · 187 · 291910.1016/j.cell.2024.04.033 ↗
25. 10.1016/j.celrep.2020.10803710.1016/j.celrep.2020.108037 ↗
26. 10.1016/j.isci.2021.10298710.1016/j.isci.2021.102987 ↗
27. 10.1146/annurev.biophys.28.1.31910.1146/annurev.biophys.28.1.319 ↗
28. 10.1021/jacs.6b0346010.1021/jacs.6b03460 ↗
29. Huarte N. · Sci. Rep · 2016 · 6 · 3419010.1038/srep34190 ↗
30. 10.1016/j.bpj.2017.06.06110.1016/j.bpj.2017.06.061 ↗
31. Chojnacki J. · Nat. Commun. · 2017 · 8 · 54510.1038/s41467-017-00515-6 ↗
32. 10.1002/jcc.2094510.1002/jcc.20945 ↗
33. Carravilla P. · Nat. Commun. · 2019 · 10 · 7810.1038/s41467-018-07962-9 ↗
34. 10.1016/j.chemphyslip.2021.10511710.1016/j.chemphyslip.2021.105117 ↗
35. 10.1021/bi002903a10.1021/bi002903a ↗
36. 10.1074/jbc.M117.77542910.1074/jbc.M117.775429 ↗
37. 10.1073/pnas.051113610310.1073/pnas.0511136103 ↗
38. 10.1103/PhysRevLett.81.501910.1103/PhysRevLett.81.5019 ↗
39. 10.1038/nrm.2017.1610.1038/nrm.2017.16 ↗
40. 10.1038/s41589-020-0529-610.1038/s41589-020-0529-6 ↗
41. Zhang L. · Nat. Commun. · 2019 · 10 · 538910.1038/s41467-019-12973-1 ↗
42. Stano A. · J. Virol · 2017 · 91 · e0041510.1128/JVI.00415-17 ↗
43. 10.1128/JVI.02566-1310.1128/JVI.02566-13 ↗
44. 10.1021/acsinfecdis.0c0024310.1021/acsinfecdis.0c00243 ↗
45. 10.1016/S0006-3495(98)77849-X10.1016/S0006-3495(98)77849-X ↗
46. 10.1039/D1NR03084A10.1039/D1NR03084A ↗
47. 10.1039/D3NR03164K10.1039/D3NR03164K ↗
48. 10.1021/acs.biomac.6b0014610.1021/acs.biomac.6b00146 ↗
49. 10.1038/s41580-022-00524-410.1038/s41580-022-00524-4 ↗
50. Torralba J. · Commun. Biol. · 2022 · 5 · 126510.1038/s42003-022-04219-6 ↗
51. Pinto D. · Cell Host Microbe · 2019 · 26 · 62310.1016/j.chom.2019.09.016 ↗
52. van den Brink-van der Laan E. · Biochim. Biophys. Acta · 2004 · 1666 · 27510.1016/j.bbamem.2004.06.010 ↗
53. 10.1146/annurev.biochem.72.121801.16150410.1146/annurev.biochem.72.121801.161504 ↗
54. 10.1039/c3sm51829a10.1039/c3sm51829a ↗
55. Pohnl M. · Nat. Commun. · 2023 · 14 · 803810.1038/s41467-023-43892-x ↗
56. 10.1021/la900395w10.1021/la900395w ↗
57. 10.1016/j.bbamem.2020.18346710.1016/j.bbamem.2020.183467 ↗
58. Corey L. · N Engl J. Med. · 2021 · 384 · 100310.1056/NEJMoa2031738 ↗
59. 10.1529/biophysj.104.04870210.1529/biophysj.104.048702 ↗
60. 10.1063/1.47064810.1063/1.470648 ↗
61. 10.1063/1.46746810.1063/1.467468 ↗
62. 10.1002/jcc.2028910.1002/jcc.20289 ↗
63. 10.1021/jp101759q10.1021/jp101759q ↗
64. 10.1063/1.44586910.1063/1.445869 ↗
65. 10.1002/jcc.2482910.1002/jcc.24829 ↗
66. 10.1063/1.46439710.1063/1.464397 ↗
67. 10.1103/PhysRev.159.9810.1103/PhysRev.159.98 ↗
68. 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H ↗
69. 10.1063/1.46313710.1063/1.463137 ↗
70. 10.1016/j.softx.2015.06.00110.1016/j.softx.2015.06.001 ↗